The global Type 2 Diabetes (T2D) market is estimated to be $31.3 billion in 2014 and is expected to grow at a CAGR of mid-range single digit from 2015 to 2021 to reach $46.7 billion by 2021

1. Current marketed and late stage
clinical pipeline is focused on
GLP1, DPP4 & SGLT2 inhibitors,
where as Discovery, Preclinical &
early clinical stages are filled with
GPR119 agonists, GLP1&GCGR
agonists, AMPK activators, GK
activators, GCGR antagonists,
DGAT1 inhibitors & 11beta-HSD1
inhibitors
IQ4I RESEARCH & CONSULTANCY
“Type 2 Diabetes (T2D) Pipeline Analysis” gives comprehensive insight on the various drugs
being developed for the treatment of T2D. The report covers all the drugs being developed in
various phases (Discovery, Preclinical, Clinical & Marketing). The pipeline focuses on novel
pharmacologic drugs & regenerative medicines covering small molecules, monoclonal
antibodies, stem cell therapies, Gene therapies, Recombinant proteins and RNA-based
therapeutics, but excludes symptom relief drugs, generic combinations. The report also covers
some of the hot targets in research for T2D treatments and disease progression biomarkers.
This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual
researchers, Investors, Medical technology companies, Service providers and other associated
stake holders to identify and analyze the available licensing/collaborative commercial
opportunities in the Type 2 Diabetes (T2D) Drug market. The report also provide strategic
insights on medicines that are likely to have an impact on T2D treatment space and potentially
alter standards of care in T2D in the foreseeable future.
Current therapies are focused on the treatment of hyperglycemia
than on pancreatic Beta cell dysfunction and they lose efficacy
over time as both endogenous insulin secretion and insulin
sensitivity decrease. There is a need for type 2 diabetes
therapies that act in concert with available agents to provide
adequate glycemic control without causing hypoglycemia
and weight gain, which are associated with increase in
cardiovascular risk. Hence, it provides a tremendous
opportunity for upcoming therapies specific to T2D such as
MAbs, stem cell-based, gene therapies and RNA-based
therapies. These modalities may provide beta-cell protection,
regeneration, mass increase with additional benefits of weight
loss, triglyceride lowering and kidney protection.
TYPE 2 DIABETES (T2D)
PIPELINE ANALYSIS

2. Key Findings:
 The global Type 2 Diabetes (T2D) market is estimated to be $31.3 billion in 2014 and is
expected to grow at a CAGR of mid-range single digit from 2015 to 2021 to reach $46.7
billion by 2021
 Factors contributing to the market growth include,
technological advancements leading to emergence of
novel therapeutics & mechanisms, increasing incidence
of diabetes, obesity & cardiac diseases, alteration in
lifestyle and high unmet needs in current treatments
options.
 IQ4I analysis indicates that 37% of candidates are in
Pre-clinical stage followed by 20% in PII clinical
 In addition to small molecules, there is growing interest
among researchers on large molecules and novel
therapies, such as
o RNA-based therapy
o Stem cell therapy
o Monoclonal antibody-based therapy
o Gene therapy
o Recombinant proteins
Some of the key sections covered in the report are given below:
Epidemiology
In this section, epidemiology of T2D is reviewed to understand potential significance and impact
of the disease.
 Global T2D prevalence rates
Hot Targets, Mechanisms & Therapies
In this section, various T2D associated targets, mechanism and upcoming therapies are
discussed. Also, covers novel targets in early research for diabetes along with disease
progression biomarkers associated with T2D.
Market analysis
In market analysis section, global Type 2 Diabetes (T2D) drugs market is indicated region-wise
along with the CAGRs forecasted from 2015-2021.
 Forecasting model for T2D market
 T2D market dynamics
 Global and regional T2D drugs market
 Cost-burden diabetes care in U.S
Preclinical
Discovery
Marketed
PR, REG & APP
Clinical
Phase II
Phase I

3. Pipeline Analysis
Pipeline analysis was carried to get deeper insights on various treatment modalities in
discovery, development & marketing section, pipelines from major companies were identified
and Potential targets were reported along with Mechanism of
action, Current development status & nature of molecule.
 Pipeline analysis by developmental stage (Discovery to
Marketing)
 Pipeline analysis by modalities
o Monoclonal Antibodies pipeline analysis
o RNA-therapeutics pipeline analysis
o Stem cell therapy pipeline analysis
o Gene therapy pipeline analysis
o Recombinant protein pipeline analysis
 Pipeline analysis by leading players & Target analysis
 Drug analysis based on mechanism (alpha-cell secretion, alpha-cell mass decline,
kidney protection, insulin sensitizers, Triglyceride lowering, weight loss, β-cell mass
increase, β-cell mass decline, β-cell protection & β-cell regeneration).
Key Players Analysis
The key player’s analysis section provides an in-depth understanding of various companies
working on Type 2 Diabetes (T2D) and their Pipelines with development phase as well as
understanding partnering strategies such as deals entered by the company.
 Global key players overview
 Global key players Pipeline data (Discovery, Pre-clinical, Clinical & Marketing)
 Global key players deals (Collaborations, Licensing, Service agreements, grants, funds)
IQ4I Research & Consultancy Pvt. Ltd. +91 80 60500229
No- 11, 1st
Stage, W. Cord Road www.iq4i.com
Rajaji Nagar, Bangalore- 560010, INDIA bd@iq4i.com
No.ofmolecules
Small molecules
Large molecules
Monoclonal
antibodies
Recombinant
Proteins
Stem cell therapy
RNA based therapy